XMT-2056: A Her-2 Targeted Immunosynthen STING agonist antibody drug conjugate
August, 2022
XMT-2056: A Her-2 Targeted Immunosynthen STING agonist antibody drug conjugate
August, 2022
XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab
April, 2022
Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potential anti-tumor activity by delivering STING agonist specifically to tumor cells and FcγRI-expressing subset of myeloid cells
April, 2022
STING-Agonist ADCs Targeting Tumor-Associated Antigens Coordinate Immune-Mediated Killing of Antigen-Negative Cancer Cells
XMT-2056: Tumor-targeted Innate Immune Activation via a STING-agonist Antibody Drug Conjugate
October, 2021
XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity
April, 2021
Tumor cell-intrinsic STING pathway activation leads to robust induction of Type III Interferons and contributes to the anti-tumor activity elicited by STING agonism
April, 2021
Immunosynthen: STING-Agonist ADC Platform
November 2020